STAG2 and acute myeloid leukemia: We observed that STAG2-mutant AML had significantly worse OS than AML-non-MR (HR = 0.62, 95% CI = 0.5–0.76, median OS 16 vs. 35 months, p < 0.001), and only a modestly better OS than AML-MR (HR = 1.43, 95% CI = 1.16–1.77, median OS 10.3, p < 0.001, Fig. 4C).